Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 501 - 525 of 11588 in total

Benzoic acid

A fungistatic compound that is widely used as a food preservative. It is conjugated to GLYCINE in the liver and excreted as hippuric acid. As the sodium salt form, sodium benzoate is used as a treatment for urea cycle disorders due to its ability to bind amino acids. This leads...
Approved
Investigational
Matched Description: … A fungistatic compound that is widely used as a food preservative. ... This leads to excretion of these amino acids and a decrease in ammonia levels. ... As the sodium salt form, sodium benzoate is used as a treatment for urea cycle disorders due to its ability …
Matched Categories: … Compounds used in a research, industrial, or household setting …

Molybdenum

Molybdenum is a chemical element with symbol Mo and atomic number 42. As it is not a naturally occuring free metal on Earth, molybdenum is found only in various oxidation states in minerals. Molybdenum is commonly used in metallurgy and other chemical applications however it has essential biological roles in...
Approved
Matched Description: … Molybdenum is a chemical element with symbol Mo and atomic number 42. ... As it is not a naturally occuring free metal on Earth, molybdenum is found only in various oxidation ... It is an essential trace dietary element and acts as a critical cofactor in several molybdenum-dependent …
Matched Mixtures name: … ONE A DAY TABLET ... Extra Once A Day ... Maximum Once A Day …

Sodium zirconium cyclosilicate

Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. It is administered orally and is odorless, tasteless, and stable at room temperature. Approval...
Approved
Investigational
Matched Description: … powder for oral suspension that acts as a highly selective potassium removing agent. ... Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a …
Matched Categories: … Compounds used in a research, industrial, or household setting …

Bromocriptine

Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptine has been...
Approved
Investigational
Withdrawn
Matched Description: … Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity …

Sulfathiazole

Sulfathiazole is a short-acting sulfa drug. It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide. Except for those formulated for vaginal use, the FDA withdrew its approval for the use of...
Approved
Vet approved
Withdrawn
Matched Description: … Sulfathiazole is a short-acting sulfa drug. ... It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. …

Technetium Tc-99m disofenin

Technetium Tc-99m disofenin is a radiopharmaceutical agent used in hepatobiliary imaging for diagnostic purposes. It is well suited for both planar and single photon tomographic scintigraphy to quantitatively measure the function of liver, gallbladder and bile ducts and detect any anatomical changes in the hepatobliary system. It is available as...
Approved
Matched Description: … It is available as an intravenous injection in a preparation kit under the name Hepatolite. ... Technetium Tc-99m disofenin is a radiopharmaceutical agent used in hepatobiliary imaging for diagnostic ... Technetium Tc-99m is a metastable nuclear isomer and disofenin is an iminodiacetic acid derivative with …
Matched Categories: … Compounds used in a research, industrial, or household setting …

Thalidomide

A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha...
Approved
Investigational
Withdrawn
Matched Description: … A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn ... It has been reintroduced and used for a number of inflammatory disorders and cancers. ... activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) …

Aceclofenac

Aceclofenac is an oral non-steroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and analgesic properties used to treat osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. It is reported to have a higher anti-inflammatory action or at least comparable effects than conventional NSAIDs in double-blind studies [A19667, A19668, A19670]. Aceclofenac potently inhibits the...
Approved
Investigational
Matched Description: … It is a more commonly prescribed drug in Europe. ... It is reported to have a higher anti-inflammatory action or at least comparable effects than conventional ... In 1991, aceclofenac was developed as an analog of a commonly prescribed NSAID, [DB00586], via chemical …

Velaglucerase alfa

Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease.
Approved
Investigational
Matched Description: … Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. ... Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of …

Potassium acetate

Approved
Investigational

Chloroquine

Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine. Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a...
Approved
Investigational
Vet approved
Matched Description: … Chloroquine and its derivative [hydroxychloroquine] have since been repurposed for the treatment of a …

Tildrakizumab

Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy...
Approved
Investigational
Matched Description: … A study was performed on the pharmacokinetics of this drug on various ethnicities. ... Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows ... The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every …

Vemurafenib

Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann...
Approved
Matched Description: … Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E ... After approval, Roche in collaboration with Genentech launched a broad development program. [L1012] …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Methadone

Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain transmission. It also has a...
Approved
Matched Description: … , and a long duration of action. ... Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate ... However, it also has a unique pharmacokinetic profile. …

Sotagliflozin

Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind, which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m2. Its potency in inhibiting SGLT2 is similar...
Approved
Investigational
Matched Description: … [L39734] A similar approval has also been sought in the US, but the FDA has since published a proposal ... Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind,[A244499] which is approved ... combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a …

Sulconazole

Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis infections.[L44592,L44597] Sulconazole appears to be effective...
Approved
Matched Description: … Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream …

Oxetacaine

Oxetacaine, also called oxethazaince, is a potent surface analgesic with the molecular formula N, N-bis-(N-methyl-N-phenyl-t-butyl-acetamide)-beta-hydroxyethylamine that conserves its unionized form at low pH levels. Its actions have shown to relieve dysphagia, relieve pain due to reflux, chronic gastritis, and duodenal ulcer. Oxetacaine is approved by Health Canada since 1995 for...
Approved
Investigational
Matched Description: … Oxetacaine, also called oxethazaince, is a potent surface analgesic with the molecular formula N, N-bis …

Regadenoson

Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.
Approved
Investigational
Matched Categories: … Adenosine A receptor agonists …

Heparin

Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor...
Approved
Investigational
Matched Description: … It is a naturally occurring anticoagulant released from mast cells. ... Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers ... infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a …

Mirabegron

Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is...
Approved
Matched Description: … Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of ... Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment …

Luspatercept

Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1.[A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients...
Approved
Investigational
Matched Description: … Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin …

Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen

Approved

Doripenem

Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that...
Approved
Investigational
Matched Description: … Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen ... found that doripenem carried an increased risk of death and lower clinical cure rates, resulting in a ... The FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated …

Apadamtase alfa

Thrombotic thrombocytopenic purpura (TTP) is a rare blood clotting disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and various degrees of organ damage. It may be inherited (congenital TTP; cTTP) or acquired due to autoantibodies (immune-mediated TTP; iTTP), although cTTP accounts for <5% of all cases of TTP. Patients with cTTP...
Approved
Investigational
Matched Description: … [A262076] Patients with cTTP have a severe deficiency of a plasma metalloproteinase called ADAMTS13 ( ... a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), which is responsible ... Thrombotic thrombocytopenic purpura (TTP) is a rare blood clotting disorder characterized by thrombocytopenia …

Ethambutol

Ethambutol is a bacteriostatic agent indicated alongside medications such as isoniazid, rifampin, and pyrazinamide in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of Mycobacterium tuberculosis. Ethambutol was granted FDA...
Approved
Matched Description: … Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], ... [A229048] It was developed out of a need for therapies active against isoniazid resistant strains of …
Displaying drugs 501 - 525 of 11588 in total